| Symbol | ELVN |
|---|---|
| Name | ENLIVEN THERAPEUTICS, INC. |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Pharmaceutical Preparations |
| Address | 6200 LOOKOUT ROAD, BOULDER, CO 80301 |
| Telephone | 720-647-8519 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001672619 |
| Description | None |
Hohl Benjamin 🟡 adjusted position in 6.0K shares (1 derivative) of Enliven Therapeutics, Inc. (ELVN) at $53.87 Transaction Date: Jul 17, 2026 | Filing ID: 000006
Read moreCollins Helen Louise 🟡 adjusted position in 5.0K shares (1 derivative) of Enliven Therapeutics, Inc. (ELVN) at $53.92 Transaction Date: Jul 17, 2026 | Filing ID: 000011
Read more📋 Collins Helen Louise (Officer) plans to sell 15K shares of Enliven Therapeutics, Inc. (at $50.86 each, total $763K) Filed: Jul 17, 2026 | ID: 000084
Read moreORBIMED ADVISORS LLC 🔴 sold 860.1K shares of Enliven Therapeutics, Inc. (ELVN) at $45.38 ($39.0M) Transaction Date: Jun 22, 2026 | Filing ID: 000653
Read moreNew Form SCHEDULE 13D/A - Enliven Therapeutics, Inc. <b>Filed:</b> 2026-06-24 <b>AccNo:</b> 0000947871-26-000651 <b>Size:</b> 30 KB
Read more📋 OrbiMed Genesis Master Fund, L.P. (Shareholder) plans to sell 25K shares of Enliven Therapeutics, Inc. (at $45.96 each, total $1.1M) Filed: Jun 22, 2026 | ID: 000650
Read more📋 OrbiMed Private Investments VII, LP (Shareholder) plans to sell 787K shares of Enliven Therapeutics, Inc. (at $45.96 each, total $36.2M) Filed: Jun 22, 2026 | ID: 000649
Read more📋 The Biotech Growth Trust PLC (Shareholder) plans to sell 29K shares of Enliven Therapeutics, Inc. (at $45.96 each, total $1.4M) Filed: Jun 22, 2026 | ID: 000648
Read moreHohl Benjamin 🟡 adjusted position in 6.0K shares (1 derivative) of Enliven Therapeutics, Inc. (ELVN) at $44.75 Transaction Date: Jun 17, 2026 | Filing ID: 000005
Read moreCollins Helen Louise 🟡 adjusted position in 5.0K shares (1 derivative) of Enliven Therapeutics, Inc. (ELVN) at $44.74 Transaction Date: Jun 17, 2026 | Filing ID: 000010
Read more